# China Pharma Holdings, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/China Pharma Holdings, Inc). ## Overview China Pharma Holdings, Inc. is a Nevada holding company whose operating business is conducted in China through its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. Helpson develops, manufactures, and markets prescription pharmaceutical products for human use, with a focus on high-incidence and high-mortality diseases prevalent in the PRC. Its portfolio includes dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The company sells substantially all of its products through local GSP-certified drug distributors, which then supply state-owned hospitals. China Pharma’s business is shaped by Chinese healthcare distribution practices, regulatory approvals from the NMPA, and working-capital pressure from long collection cycles. ## Products & services • Dry powder injectables for prescription use • Liquid injectables for hospital treatment • Tablets and capsules • Cephalosporin oral solutions • CNS Cerebral & Cardio Vascular products • Anti-Viral/Infection & Respiratory products • Digestive Diseases products - **Anti-Viral/Infection & Respiratory** (63%) — Prescription drugs used to treat infectious and respiratory conditions sold through Chinese distributors and hospitals. - **CNS Cerebral & Cardio Vascular** (30%) — Products used for central nervous system and cardiovascular indications, including injectable therapies. - **Digestive Diseases** (5%) — Products such as omeprazole used for digestive and gastrointestinal conditions. - **Other** (2%) — Smaller product lines not included in the core therapeutic categories disclosed by management. - Dry powder injectables for prescription use - Liquid injectables for hospital treatment - Tablets and capsules - Cephalosporin oral solutions - CNS Cerebral & Cardio Vascular products - Anti-Viral/Infection & Respiratory products - Digestive Diseases products ## Customers The company primarily sells to local drug distributors in China rather than directly to hospitals or patients. These distributors are typically GSP-certified and act as the channel through which products reach state-owned hospitals, which are the end-use buyers in the Chinese healthcare system. China Pharma’s customer base is therefore shaped by the hospital procurement process, regulatory logistics requirements, and the payment behavior of public hospitals. The company also appears dependent on a relatively small number of channel customers, which increases concentration and credit exposure. Because payment is often delayed until hospitals pay distributors, customer quality is closely tied to receivables collection and bad-debt risk. - **GSP-certified drug distributors** (primary) — Primary buyers that purchase from Helpson and resell into the hospital channel; they buy because they are licensed to handle pharmaceutical circulation and are the practical route to market. - **State-owned hospitals** (primary) — End-market users that ultimately consume the products and drive distributor demand; they buy prescription medicines for inpatient and outpatient treatment. - **Chinese public healthcare system** (secondary) — Institutional demand base for approved medicines used in common disease areas, especially where procurement is centralized or hospital-led. - **Prescription drug channel partners** (secondary) — Regional pharmaceutical intermediaries that distribute approved products and support market access in China. - GSP-certified drug distributors that purchase product for resale - State-owned hospitals as the end-market that ultimately drives demand - Chinese healthcare channel buyers that need NMPA-approved medicines - Customers needing prescription injectables and hospital-use therapies - Buyers that accept long payment terms due to industry practice - Channel partners that value approved products with established indications ## Geography China is the company’s only meaningful operating geography, because all operations are conducted through Helpson in the PRC. Manufacturing facilities are located in China, and the company’s products are sold into the Chinese pharmaceutical market. The business is exposed to PRC regulatory controls, including NMPA approvals, GSP distribution standards, and foreign-exchange restrictions on RMB conversion and remittance. Management also notes that cash held in the Chinese subsidiary is considered reinvested indefinitely and may not be readily available to the U.S. parent. This makes the company highly dependent on Chinese operating conditions, healthcare policy, and capital controls. - **China** (100%) — All operating activities are conducted in the PRC through Helpson. - Operations are conducted in the PRC through Helpson - Manufacturing facilities are located in China - Sales are concentrated in the Chinese pharmaceutical market - Products depend on NMPA approvals and PRC distribution rules - RMB controls can restrict cash movement to the U.S. parent - Cash in the Chinese subsidiary is not readily available upstream ## Strategy China Pharma’s near-term strategy appears centered on maintaining access to working capital, preserving distributor relationships, and supporting the launch of new products. Management highlights bank lines of credit, CEO advances, and a convertible note as important liquidity sources, which suggests financing is a core strategic priority rather than a side issue. The company also emphasizes product development and commercialization, but its ability to execute is constrained by going-concern risk and limited cash resources. In parallel, it is managing receivables, inventory, and credit losses to keep the distribution model functioning in a delayed-payment environment. Longer term, the company’s competitive position depends on sustaining NMPA-approved products and adapting to centralized procurement pressure in China. - **Maintain liquidity and refinancing access** (short-term) — The company needs external funding to support operations and avoid disruption given limited cash and going-concern pressure. - **Launch and commercialize new products** (medium-term) — New products can reduce dependence on a few therapeutic categories and support revenue growth in a competitive market. - **Improve working-capital discipline** (short-term) — Long distributor payment cycles and receivable write-offs make cash conversion a key determinant of business continuity. - Secure liquidity through bank lines of credit and external financing - Use CEO funding and convertible debt to bridge working-capital needs - Launch new products to broaden the portfolio and reduce concentration - Maintain distributor relationships in a delayed-payment market - Manage receivables and credit losses to protect cash flow - Adapt product mix to procurement and market-fluctuation pressures ## Risks The most immediate risk is liquidity and going-concern pressure, because the company relies on external financing, CEO support, and bank credit to fund operations. Credit risk is also material: the business sells through distributors that often wait for payment from state-owned hospitals, creating long collection cycles and exposure to bad debts. The company is exposed to Chinese healthcare policy changes, including centralized procurement and NMPA logistics requirements, which can shift product demand and pricing. Foreign-exchange and capital-control restrictions in the PRC may limit the parent company’s ability to access cash generated by the subsidiary. More generally, the company faces pharmaceutical industry risks such as regulatory approvals, product concentration, pricing pressure, and inventory obsolescence. - **Going-concern and financing dependence** [critical] — Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. - **Credit losses and receivables collection** [high] — Customers are distributors paid after state-owned hospitals settle, which creates long collection periods and write-off risk. - **PRC regulatory and procurement changes** [high] — NMPA rules, GSP requirements, and centralized procurement can alter market access, pricing, and product mix. - **Foreign exchange and capital controls** [medium] — RMB conversion and remittance restrictions may limit the parent’s access to cash held in China. - Going-concern and liquidity risk due to limited cash and reliance on financing - Credit losses from long distributor payment cycles and hospital reimbursement delays - Centralized procurement and pricing pressure in the Chinese pharmaceutical market - Regulatory risk tied to NMPA approvals and distribution compliance - Foreign-exchange controls that may restrict cash upstreaming from China - Product concentration risk across a small number of therapeutic categories ## Accounting Receivables and credit-loss accounting are especially important because the company operates in a delayed-payment distribution model and has recorded large write-offs of aged receivables. Management uses customer-specific review procedures and adjusts the allowance for credit losses based on expected recoverability, which can materially affect earnings and balance-sheet quality. Revenue is also subject to quarterly fluctuation by product category, so period-to-period comparisons can be distorted by product mix changes and market volatility. Inventory valuation matters because the company carries pharmaceutical inventory in a regulated market where product demand, procurement policy, and shelf-life can affect realizable value. In addition, cash held in the PRC is treated as reinvested indefinitely, and foreign-exchange controls may affect the presentation of liquidity and upstream cash availability. - **Allowance for credit losses** — Can materially affect operating results and net receivables - **Receivable write-offs** — Can create significant one-time charges and reduce assets - **Inventory valuation** — Can affect cost of goods sold and gross margin - **Foreign currency translation and cash restrictions** — Affects liquidity analysis and parent-level cash access - Allowance for credit losses can swing materially with distributor collections - Large write-offs of aged receivables can distort quarterly earnings - Revenue mix changes by therapeutic category affect comparability across periods - Inventory valuation is sensitive to procurement policy and product demand - Cash in China may be restricted from upstream transfer to the parent - Foreign currency translation and RMB controls affect reported liquidity --- *Last updated: 2026-08-11T04:46:25.899520+00:00*